TNF binders

Patent metadata

Field	Value
Publication number	US-10544211-B2
Application number	US-201615501011-A
Country	US
Kind code	B2
Filing date	Nov 14, 2016
Priority date	Nov 12, 2015
Publication date	Jan 28, 2020
Grant date	Jan 28, 2020

Abstract

The present invention relates to amino acid sequences, compounds and polypeptides binding to tumor necrosis factor alpha (“TNF” or “TNF-alpha”). In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVDs”) binding to tumor necrosis factor alpha, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs, collectively TNF binders. Other aspects, embodiments, features, uses and advantages of the invention will be clear to the skilled person based on the disclosure herein.

First claim

The invention claimed is:

1. An immunoglobulin single variable domain (ISVD), comprising:
a CDR1 (according to Abm) that is the amino acid sequence GFTFSTADMG (SEQ ID NO: 5); and
a CDR2 (according to Abm) that is the amino acid sequence RISGIDGTTY (SEQ ID NO: 6); and
a CDR3 (according to Abm) that is the amino acid sequence PRYADQWSAYDY (SEQ ID NO: 4),
wherein the ISVD specifically binds to tumor necrosis factor; and
wherein the ISVD does not comprise the amino acid sequence of SEQ ID NO: 40.

2. An immunoglobulin single variable domain (ISVD), comprising
a CDR1 (according to Abm) that is the amino acid sequence GFTFSTADMG (SEQ ID NO: 5); and
a CDR2 (according to Abm) that is the amino acid sequence RISGIDGTTY (SEQ ID NO: 6); and
a CDR3 (according to Abm) that is the amino acid sequence PRYADQWSAYDY (SEQ ID NO: 4),
wherein the amino acid residue at position 49 is an alanine,
wherein the amino acid residue at position 74 is serine,
wherein the amino acid residue at position 73 is N and the amino acid residue at position 75 is K,
wherein the positions are determined according to Kabat numbering,
wherein the ISVD specifically binds to tumor necrosis factor, and
wherein the ISVD does not comprise the amino acid sequence of SEQ ID NO: 40.

3. An immunoglobulin single variable domain, comprising the amino acid sequence of SEQ ID NO: 39 or SEQ ID NO: 36.

4. An immunoglobulin single variable domain, consisting of the amino acid sequence of SEQ ID NO: 39 or SEQ ID NO: 36.

Assignees

• Ablynx Nv

Inventors

• Buyse Marie-Ange
• Boucneau Joachim
• Casteels Peter
• Van Heeke Gino

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

• A61P1/02

  Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title